Logo image of ONCT

Oncternal Therapeutics Inc (ONCT) Stock Fundamental Analysis

NASDAQ:ONCT - Nasdaq - US68236P2065 - Common Stock - Currency: USD

0.5266  -0.17 (-24.11%)

After market: 0.61 +0.08 (+15.84%)

Fundamental Rating

2

ONCT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While ONCT seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, ONCT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ONCT had negative earnings in the past year.
ONCT had a negative operating cash flow in the past year.
ONCT had negative earnings in each of the past 5 years.
ONCT had a negative operating cash flow in each of the past 5 years.
ONCT Yearly Net Income VS EBIT VS OCF VS FCFONCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

ONCT has a Return On Assets of -221.62%. This is amonst the worse of the industry: ONCT underperforms 91.70% of its industry peers.
Looking at the Return On Equity, with a value of -377.95%, ONCT is doing worse than 77.39% of the companies in the same industry.
Industry RankSector Rank
ROA -221.62%
ROE -377.95%
ROIC N/A
ROA(3y)-68.44%
ROA(5y)-75.41%
ROE(3y)-79.79%
ROE(5y)-98.7%
ROIC(3y)N/A
ROIC(5y)N/A
ONCT Yearly ROA, ROE, ROICONCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ONCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONCT Yearly Profit, Operating, Gross MarginsONCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K -4K -5K

More info and screens

5

2. Health

2.1 Basic Checks

ONCT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ONCT has been increased compared to 5 years ago.
ONCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ONCT Yearly Shares OutstandingONCT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
ONCT Yearly Total Debt VS Total AssetsONCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -26.66, we must say that ONCT is in the distress zone and has some risk of bankruptcy.
ONCT has a worse Altman-Z score (-26.66) than 90.11% of its industry peers.
ONCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -26.66
ROIC/WACCN/A
WACCN/A
ONCT Yearly LT Debt VS Equity VS FCFONCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 2.39 indicates that ONCT has no problem at all paying its short term obligations.
With a Current ratio value of 2.39, ONCT is not doing good in the industry: 71.73% of the companies in the same industry are doing better.
A Quick Ratio of 2.39 indicates that ONCT has no problem at all paying its short term obligations.
ONCT's Quick ratio of 2.39 is on the low side compared to the rest of the industry. ONCT is outperformed by 70.32% of its industry peers.
Industry RankSector Rank
Current Ratio 2.39
Quick Ratio 2.39
ONCT Yearly Current Assets VS Current LiabilitesONCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.82% over the past year.
ONCT shows a strong growth in Revenue. In the last year, the Revenue has grown by 227.92%.
The Revenue for ONCT have been decreasing by -38.50% on average. This is quite bad
EPS 1Y (TTM)18.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.88%
Revenue 1Y (TTM)227.92%
Revenue growth 3Y-38.5%
Revenue growth 5YN/A
Sales Q2Q%175.98%

3.2 Future

ONCT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.92% yearly.
Based on estimates for the next years, ONCT will show a small growth in Revenue. The Revenue will grow by 3.60% on average per year.
EPS Next Y10.27%
EPS Next 2Y10.73%
EPS Next 3Y15.35%
EPS Next 5Y9.92%
Revenue Next Year161.75%
Revenue Next 2Y-2.29%
Revenue Next 3Y16.74%
Revenue Next 5Y3.6%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ONCT Yearly Revenue VS EstimatesONCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1M 2M 3M 4M
ONCT Yearly EPS VS EstimatesONCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ONCT. In the last year negative earnings were reported.
Also next year ONCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONCT Price Earnings VS Forward Price EarningsONCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONCT Per share dataONCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as ONCT's earnings are expected to grow with 15.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.73%
EPS Next 3Y15.35%

More info and screens

0

5. Dividend

5.1 Amount

ONCT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Oncternal Therapeutics Inc

NASDAQ:ONCT (12/2/2024, 8:00:01 PM)

After market: 0.61 +0.08 (+15.84%)

0.5266

-0.17 (-24.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners12.07%
Inst Owner Change-3.69%
Ins Owners155.35%
Ins Owner Change0%
Market Cap1.56M
Analysts43.33
Price Target2.04 (287.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.49%
Min EPS beat(2)8.75%
Max EPS beat(2)12.24%
EPS beat(4)4
Avg EPS beat(4)6.29%
Min EPS beat(4)0.6%
Max EPS beat(4)12.24%
EPS beat(8)7
Avg EPS beat(8)3.47%
EPS beat(12)11
Avg EPS beat(12)6.79%
EPS beat(16)12
Avg EPS beat(16)5.27%
Revenue beat(2)2
Avg Revenue beat(2)241.44%
Min Revenue beat(2)230.65%
Max Revenue beat(2)252.23%
Revenue beat(4)4
Avg Revenue beat(4)202.6%
Min Revenue beat(4)111.77%
Max Revenue beat(4)252.23%
Revenue beat(8)6
Avg Revenue beat(8)96.43%
Revenue beat(12)8
Avg Revenue beat(12)59.15%
Revenue beat(16)10
Avg Revenue beat(16)55.05%
PT rev (1m)-90.24%
PT rev (3m)-92.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-15.93%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-24.31%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.72
P/FCF N/A
P/OCF N/A
P/B 0.17
P/tB 0.17
EV/EBITDA N/A
EPS(TTM)-11.69
EYN/A
EPS(NY)-10.45
Fwd EYN/A
FCF(TTM)-9
FCFYN/A
OCF(TTM)-9
OCFYN/A
SpS0.73
BVpS3.09
TBVpS3.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -221.62%
ROE -377.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-68.44%
ROA(5y)-75.41%
ROE(3y)-79.79%
ROE(5y)-98.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.39
Quick Ratio 2.39
Altman-Z -26.66
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.88%
EPS Next Y10.27%
EPS Next 2Y10.73%
EPS Next 3Y15.35%
EPS Next 5Y9.92%
Revenue 1Y (TTM)227.92%
Revenue growth 3Y-38.5%
Revenue growth 5YN/A
Sales Q2Q%175.98%
Revenue Next Year161.75%
Revenue Next 2Y-2.29%
Revenue Next 3Y16.74%
Revenue Next 5Y3.6%
EBIT growth 1Y18.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.4%
OCF growth 3YN/A
OCF growth 5YN/A